2020 Announcements

CLINUVEL
Posted by CLINUVEL
September 14, 2020

First patient dosed in SCENESSE® DNA Repair Program

Xeroderma pigmentosum (XP) patient receives SCENESSE® treatment CLINUVEL PHARMACEUTICALS LTD today announced...

Read More
CLINUVEL
Posted by CLINUVEL
September 10, 2020

SCENESSE® in DNA Repair

CLINUVEL to confirm cellular DNA repair in rare disease xeroderma pigmentosum (XP)...

Read More
CLINUVEL
Posted by CLINUVEL
September 1, 2020
CLINUVEL
Posted by CLINUVEL
August 31, 2020

Opening of VALLAURIX R&D facilities in Singapore

Advanced research facilities to progress pharmaceutical, OTC products EXECUTIVE SUMMARY • CLINUVEL...

Read More
CLINUVEL
Posted by CLINUVEL
August 27, 2020
CLINUVEL
Posted by CLINUVEL
August 27, 2020

CLINUVEL Full Year Results 2020

CLINUVEL REPORTS PROFIT, RENVESTING IN BUSINESS Fourth consecutive annual positive net cash...

Read More
CLINUVEL
Posted by CLINUVEL
August 27, 2020

CLINUVEL Webinar – Preliminary Financial Results

https://www.youtube.com/watch?v=rLSYrRRR83Y&feature=emb_title

Read More
CLINUVEL
Posted by CLINUVEL
July 31, 2020
CLINUVEL
Posted by CLINUVEL
July 31, 2020

Appendix 4C – quarterly

CLINUVEL PHARMACEUTICALS LTD today announced its Appendix 4C – Quarterly Cashflow Report...

Read More
CLINUVEL
Posted by CLINUVEL
July 23, 2020

Kommuniqué IV

Liebe Aktionäre, Freunde Es stellt sich eine neue Welt dar, die darauf...

Read More
CLINUVEL
Posted by CLINUVEL
July 22, 2020

CLINUVEL Newsletter

Dear shareholders, friends, As a new world presents itself indicating that the...

Read More
CLINUVEL
Posted by CLINUVEL
July 13, 2020

PRÉNUMBRA® – New Liquid Afamelanotide Presentation

EXECUTIVE SUMMARY • PRÉNUMBRA® non-solid dosage form of afamelanotide • Active life-cycle...

Read More
We use cookies to give you the best experience.